Key facts
- Novo Nordisk reported Q2 adjusted operating profit exceeding forecasts.
- The company raised its full-year profit and sales outlook.
- Novo Nordisk is a Danish pharmaceutical company focused on diabetes and obesity medications.
- The company is competing in the obesity drug market with its Wegovy drug.
Novo Nordisk, the Danish pharmaceutical company known for its weight-loss drug Wegovy, reported second-quarter adjusted operating profit that surpassed forecasts. The company also announced an upward revision to its full-year profit and sales outlook.
Investors are closely watching Novo Nordisk's performance as it competes with Eli Lilly in the significant obesity drug market. The company's ability to sustain its turnaround and achieve longer-term growth, particularly with its new Wegovy pill, is a key focus.
Novo Nordisk A/S is a multinational pharmaceutical company headquartered in Bagsværd, Denmark. It is controlled by Novo Holdings A/S, which holds a substantial stake in the company. Novo Nordisk specializes in diabetes and obesity medications and devices, marketing its products in 168 countries. The company was formed in 1989 through the merger of two Danish companies dating back to the 1920s. It has been recognized for its sustainability efforts and is the largest pharmaceutical company in Denmark, with a market capitalization that exceeded Denmark's GDP in 2023.